The PET biomarkers were classified as positive or negativeusing statistical parametric mapping (SPM) analysis and visual assessment.Using the amyloid/tau/neurodegeneration (A/T/N) scheme, patients weregrouped as within the AD continuum, SNAP, and BN based on amyloid andneurodegeneration status. The gene discussed is MAPT; the disease is Alzheimer disease.